January 29, 2021— Hologic, Inc. announced the expansion of its ultrasound portfolio with the launch of the new SuperSonic MACH 20 ultrasound system. Hologic now offers three tiers of ultrasound technology, ensuring more facilities have access to customized ultrasound solutions to address their unique imaging needs. Each of the systems is designed to increase efficiency and diagnostic accuracy, features exceptional image quality and innovative imaging modes, and offers an intuitive user experience.
“As the leader in breast imaging, we strive daily to deliver superior health care solutions that meet the unique and ever-changing needs of our customers,” said Jennifer Meade, Hologic’s Division President, Breast and Skeletal Health Solutions. “By continuing to heavily invest in our growing ultrasound portfolio, we’re delivering on that promise. In less than a year, we’ve brought two new ultrasound systems to market through accelerated innovation, providing our customers with an array of targeted solutions designed to optimize ultrasound imaging and enhance the patient experience.”
The latest addition to Hologic’s ultrasound portfolio, the SuperSonic MACH 20 ultrasound system, provides added clinical value for general and specialty ultrasound imaging, including of the breast, liver, muscles, and tendons. It features excellent B-mode image quality and runs on the same UltraFast imaging technology that powers Hologic’s full line of SuperSonic ultrasound systems, allowing users to perform dynamic tissue stiffness evaluation with ShearWave PLUS elastography. Radiologists and sonographers also enjoy an intuitive, ergonomic user experience thanks to the SonicPad touchpad, which is designed to reduce examination time and operator fatigue and injury.
Hologic has been expanding its comprehensive portfolio of ultrasound solutions since its acquisition of SuperSonic Imagine, a pioneer in the field of ultrasound imaging.
For more information: www.hologic.com
March 24, 2023 
![A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients](/sites/default/files/styles/feed_medium/public/Screen%20Shot%202023-03-16%20at%201.46.39%20PM.png?itok=a2-uUeQz)
